VEGFA and malignant glioma: Since VEGF is known to increase vascular permeability in mature vessels and promote the proliferation of new leaky microvasculature, Vredenburgh [4] et al. have demonstrated in a phase II trial that bevacizumab, a VEGF-A inhibitor, extends the progression-free survival in patients with recurrent malignant gliomas by a factor of two or more.